CLVS - Clovis Oncology Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 SPY (-0.1%) AAPL (%) BABA (%) LZB (-13.69%) MYOV (%) V (%) DGAZ (%) NVDA (%) UGAZ (%) AVGR (%) ATNM (%) AMRN (1.63%) HIIQ (-6.78%) GS (%) GOOGL (%) GOOG (%) GDX (%) FCEL (-3.82%) FB (%) ETHUSD (%) ETCUSD (%) ENG (2.37%) DIS (%) DHR (-0.21%) DASHUSD (%)

10% or more up

CLVS - Clovis Oncology

$7.87 0.86[12.2%]

15 mins delayed data

People also watch : LLY | AZN | JNJ | ABBV | PFE | DARE

+Watchlist

10 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$7.01	Open	$7.29
Volume	6.17M	Market Cap	795.6M
Yield		Last Dividend

Day

52 Week

Teva, Bausch Could Be Next to File for B...	11/19/19
The number of pharmaceutical and biotechnology companies seeking Chapter 11 protection has nearly tripled the 10-year average in 2019 and is expected ...

Healthcare Drives Wall Street: 5 Soaring...	11/14/19
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

Edited Transcript of CLVS earnings confe...	11/13/19
Q3 2019 Clovis Oncology Inc Earnings Call

Clovis Oncology Announces Reimbursement ...	11/13/19
BOULDER, Colo.-- -- Rubraca ® offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cance...

Implied Volatility Surging for Clovis On...	11/11/19
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Were Hedge Funds Right About Dumping Clo...	11/08/19
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world pr...

Clovis (CLVS) Q3 Earnings & Sales Be...	11/08/19
Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.

Clovis Oncology (CLVS) Reports Q3 Loss, ...	11/07/19
Clovis (CLVS) delivered earnings and revenue surprises of 1.56% and 3.56%, respectively, for the quarter ended September 2019. Do the numbers hold clu...

Clovis Oncology Announces Third Quarter ...	11/07/19
BOULDER, Colo.-- -- $37.6M in Rubraca ® net product revenue for Q3 2019, up 65% year over year Net product revenue increased 14% sequentially in Q3 20...

The Daily Biotech Pulse: Obseva Sinks On...	11/07/19
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) A...

ANALYST RATINGS

4 analyst ratings (Last 6 months)

0.00 %

Strong Buy + Buy

Price Target (PT)

Hold rating	11/19/19
Evercore ISI Group downgrades from Outperform to In-Line rating and announces Price Target of $8.00

Sell rating	10/08/19
Goldman Sachs maintains Sell rating and lowers Price Target from $13.00 to $3.00

Hold rating	08/13/19
Bank of America downgrades from Buy to Neutral rating and lowers Price Target from $13.00 to $7.00

Sell rating	05/29/19
Goldman Sachs downgrades from Neutral to Sell rating and lowers Price Target from $17.00 to $15.00

EARNINGS

Date	2019-11-07 (BMO)	Est. (EPS/Rev.)	($1.89)/ 35.84M
Actual (EPS/Rev.)	$-1.85/ $37.60 M	EPS (TTM)	0

TRADERS TRACKING $CLVS

Service Name	Trader	% Success
Big Data Kornacki & Zhou	Zhou Academy	87.00 %	Subscribe
smashingdon	Paul	70.00 %	Follow
Alpha Swing Trades	Jonathan	69.00 %	Follow
Market Focus	Hao	60.00 %	Subscribe
Best Trading Ideas	Best Trading Ideas	52.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.